372 related articles for article (PubMed ID: 29982673)
1. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.
van den Berg MH; Overbeek A; Lambalk CB; Kaspers GJL; Bresters D; van den Heuvel-Eibrink MM; Kremer LC; Loonen JJ; van der Pal HJ; Ronckers CM; Tissing WJE; Versluys AB; van der Heiden-van der Loo M; Heijboer AC; Hauptmann M; Twisk JWR; Laven JSE; Beerendonk CCM; van Leeuwen FE; van Dulmen-den Broeder E;
Hum Reprod; 2018 Aug; 33(8):1474-1488. PubMed ID: 29982673
[TBL] [Abstract][Full Text] [Related]
2. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
3. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.
van der Kooi ALF; van Dijk M; Broer L; van den Berg MH; Laven JSE; van Leeuwen FE; Lambalk CB; Overbeek A; Loonen JJ; van der Pal HJ; Tissing WJ; Versluys B; Bresters D; Beerendonk CCM; Ronckers CR; van der Heiden-van der Loo M; Kaspers GL; de Vries ACH; Robison LL; Hudson MM; Chemaitilly W; Byrne J; Berger C; Clemens E; Dirksen U; Winther JF; Fosså SD; Grabow D; Haupt R; Kaiser M; Kepak T; Kruseova J; Modan-Moses D; Pluijm SMF; Spix C; Zolk O; Kaatsch P; Krijthe JH; Kremer LC; Yasui Y; Brooke RJ; Uitterlinden AG; van den Heuvel-Eibrink MM; van Dulmen-den Broeder E
Hum Reprod; 2021 Mar; 36(4):1120-1133. PubMed ID: 33582778
[TBL] [Abstract][Full Text] [Related]
4. Validity of self-reported data on pregnancies for childhood cancer survivors: a comparison with data from a nationwide population-based registry.
Overbeek A; van den Berg MH; Hukkelhoven CW; Kremer LC; van den Heuvel-Eibrink MM; Tissing WJ; Loonen JJ; Versluys AB; Bresters D; Kaspers GJ; Lambalk CB; van Leeuwen FE; van Dulmen-den Broeder E;
Hum Reprod; 2013 Mar; 28(3):819-27. PubMed ID: 23175500
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE).
van den Berg MH; van Dijk M; Byrne J; Berger C; Dirksen U; Winther JF; Fossa SD; Grabow D; Grandage VL; Haupt R; van den Heuvel-Eibrink MM; Kaiser M; Kepak T; van der Kooi ALF; Kremer LCM; Kruseova J; Lambalk CB; van Leeuwen FE; Leiper A; Modan-Moses D; Spix C; Twisk JWR; Ronckers CM; Kaatsch P; van Dulmen-den Broeder E;
Hum Reprod; 2021 May; 36(6):1561-1573. PubMed ID: 33744927
[TBL] [Abstract][Full Text] [Related]
6. Reproductive intentions and use of reproductive health care among female survivors of childhood cancer.
van Dijk M; van den Berg MH; Overbeek A; Lambalk CB; van den Heuvel-Eibrink MM; Tissing WJ; Kremer LC; van der Pal HJ; Loonen JJ; Versluys B; Bresters D; Kaspers GJL; van Leeuwen FE; van Dulmen-den Broeder E;
Hum Reprod; 2018 Jun; 33(6):1167-1174. PubMed ID: 29617794
[TBL] [Abstract][Full Text] [Related]
7. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
[TBL] [Abstract][Full Text] [Related]
8. Impact of cancer therapies on ovarian reserve.
Gracia CR; Sammel MD; Freeman E; Prewitt M; Carlson C; Ray A; Vance A; Ginsberg JP
Fertil Steril; 2012 Jan; 97(1):134-40.e1. PubMed ID: 22137491
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
[TBL] [Abstract][Full Text] [Related]
10. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.
Shandley LM; Fothergill A; Spencer JB; Mertens AC; Cottrell HN; Howards PP
Fertil Steril; 2018 Mar; 109(3):516-525.e1. PubMed ID: 29428311
[TBL] [Abstract][Full Text] [Related]
11. A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges.
Overbeek A; van den Berg MH; Kremer LC; van den Heuvel-Eibrink MM; Tissing WJ; Loonen JJ; Versluys B; Bresters D; Kaspers GJ; Lambalk CB; van Leeuwen FE; van Dulmen-den Broeder E;
BMC Cancer; 2012 Aug; 12():363. PubMed ID: 22917040
[TBL] [Abstract][Full Text] [Related]
12. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
[TBL] [Abstract][Full Text] [Related]
13. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.
Yaish I; Tordjman K; Amir H; Malinger G; Salemnick Y; Shefer G; Serebro M; Azem F; Golani N; Sofer Y; Stern N; Greenman Y
Hum Reprod; 2021 Sep; 36(10):2753-2760. PubMed ID: 34411251
[TBL] [Abstract][Full Text] [Related]
14. The effect of serum vitamin D levels on ovarian reserve markers: a prospective cross-sectional study.
Drakopoulos P; van de Vijver A; Schutyser V; Milatovic S; Anckaert E; Schiettecatte J; Blockeel C; Camus M; Tournaye H; Polyzos NP
Hum Reprod; 2017 Jan; 32(1):208-214. PubMed ID: 27927849
[TBL] [Abstract][Full Text] [Related]
15. Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.
Iwase A; Nakamura T; Nakahara T; Goto M; Kikkawa F
Reprod Sci; 2015 May; 22(5):519-26. PubMed ID: 25228631
[TBL] [Abstract][Full Text] [Related]
16. Female adolescents and young women previously treated for pediatric malignancies: assessment of ovarian reserve and gonadotoxicity risk stratification for early identification of patients at increased infertility risk.
Parissone F; Di Paola R; Balter R; Garzon S; Zaffagnini S; Neri M; Vitale V; Tridello G; Cesaro S
J Pediatr Endocrinol Metab; 2021 Jan; 34(1):25-33. PubMed ID: 33068384
[TBL] [Abstract][Full Text] [Related]
17. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
19. Ovarian response is associated with anogenital distance in patients undergoing controlled ovarian stimulation for IVF.
Fabregues F; González-Foruria I; Peñarrubia J; Carmona F
Hum Reprod; 2018 Sep; 33(9):1696-1704. PubMed ID: 30016431
[TBL] [Abstract][Full Text] [Related]
20. Diminished ovarian reserve is not observed in infertility patients with high normal CGG repeats on the fragile X mental retardation 1 (FMR1) gene.
Schufreider A; McQueen DB; Lee SM; Allon R; Uhler ML; Davie J; Feinberg EC
Hum Reprod; 2015 Nov; 30(11):2686-92. PubMed ID: 26345686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
